Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TGTX logo TGTX
Upturn stock ratingUpturn stock rating
TGTX logo

TG Therapeutics Inc (TGTX)

Upturn stock ratingUpturn stock rating
$35.16
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: TGTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 35.53%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.58B USD
Price to earnings Ratio 140.66
1Y Target Price 41.2
Price to earnings Ratio 140.66
1Y Target Price 41.2
Volume (30-day avg) 1943978
Beta 1.94
52 Weeks Range 16.65 - 46.48
Updated Date 06/19/2025
52 Weeks Range 16.65 - 46.48
Updated Date 06/19/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.25

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 10.13%
Operating Margin (TTM) 7.13%

Management Effectiveness

Return on Assets (TTM) 7.26%
Return on Equity (TTM) 19.7%

Valuation

Trailing PE 140.66
Forward PE 25.32
Enterprise Value 5458341840
Price to Sales(TTM) 14.45
Enterprise Value 5458341840
Price to Sales(TTM) 14.45
Enterprise Value to Revenue 14.13
Enterprise Value to EBITDA 77.43
Shares Outstanding 158755008
Shares Floating 135060602
Shares Outstanding 158755008
Shares Floating 135060602
Percent Insiders 9.74
Percent Institutions 63.24

Analyst Ratings

Rating 4.43
Target Price 41.2
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold -
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

TG Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

TG Therapeutics, Inc. was founded in 1993 and is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

business area logo Core Business Areas

  • Hematological Oncology: Focuses on developing and commercializing therapies for B-cell malignancies such as lymphoma and leukemia.
  • Autoimmune Diseases: Expanding focus on developing therapies for autoimmune diseases. This segment is currently more limited.

leadership logo Leadership and Structure

Michael S. Weiss is the Executive Chairman and CEO. The company has a typical structure with research, development, commercial, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • Ublituximab (Briumvi): An anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis (RMS). Revenue and market share data are still developing. Competitors include Ocrevus (Roche), Kesimpta (Novartis), and Mayzent (Novartis).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically in oncology and autoimmune disease, is highly competitive and heavily regulated. It is characterized by high R&D costs, long development timelines, and patent protection.

Positioning

TG Therapeutics is a smaller player competing with larger, more established pharmaceutical companies. Briumvi gives them a competitive advantage in the RMS market segment.

Total Addressable Market (TAM)

The TAM for multiple sclerosis therapies is estimated at $25-30 billion annually. TG Therapeutics' is focused on carving out share within the RMS sub-segment.

Upturn SWOT Analysis

Strengths

  • FDA Approved Product (Briumvi)
  • Focused Therapeutic Areas
  • Experienced Management Team
  • Novel Antibody Technology

Weaknesses

  • Limited Product Portfolio
  • High Debt Levels
  • Reliance on Single Product Revenue
  • Smaller Commercial Infrastructure Compared to Competitors

Opportunities

  • Expansion of Briumvi into New Indications
  • Strategic Partnerships and Acquisitions
  • Growth in the Autoimmune Disease Market
  • Positive Clinical Trial Results

Threats

  • Competition from Established Pharmaceutical Companies
  • Regulatory Hurdles
  • Patent Expiry
  • Unfavorable Reimbursement Policies
  • Adverse Events or Safety Concerns with Briumvi

Competitors and Market Share

competitor logo Key Competitors

  • RHHBY
  • NVS

Competitive Landscape

TG Therapeutics faces strong competition from larger pharmaceutical companies. While Briumvi offers a novel mechanism of action, competitors have established market presence and strong brand recognition.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by clinical trial successes and regulatory approvals.

Future Projections: Future growth is dependent on the commercial success of Briumvi and the advancement of other pipeline candidates. Analyst estimates vary based on these factors.

Recent Initiatives: Recent initiatives include the commercial launch of Briumvi, and continued clinical trials in autoimmune disease.

Summary

TG Therapeutics is a biotechnology company with one approved product, Briumvi, targeting the RMS market. The company faces strong competition and relies heavily on the success of Briumvi. Future growth depends on expanding Briumvi's indications, securing strategic partnerships, and overcoming regulatory and competitive hurdles. High debt levels and reliance on single product revenues remain significant challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data is subject to change and may not be entirely accurate. Consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About TG Therapeutics Inc

Exchange NASDAQ
Headquaters Morrisville, NC, United States
IPO Launch date 1995-12-14
Chairman, CEO & President Mr. Michael S. Weiss Esq.
Sector Healthcare
Industry Biotechnology
Full time employees 352
Full time employees 352

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.